(Q33392694)

26 July 2017

title

Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours (English)

1 reference

26 July 2017

1 reference

Phillip G Claringbold

1

1 reference

26 July 2017

Paul A Brayshaw

2

1 reference

26 July 2017

Richard A Price

3

1 reference

26 July 2017

J Harvey Turner

4

1 reference

26 July 2017

publication date

30 October 2010

1 reference

26 July 2017

number of pages

10

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

inferred from page(s)

published in

1 reference

26 July 2017

volume

38

1 reference

26 July 2017

issue

2

1 reference

26 July 2017

page(s)

302-311

1 reference

https://scigraph.springernature.com/pub.10.1007/s00259-010-1631-x

26 July 2017

exact match

0 references

cites work

Therapeutic options for gastrointestinal carcinoids

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1631-X

Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1631-X

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1631-X

Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1631-X

High-administered activity In-111 octreotide therapy with concomitant radiosensitizing 5FU chemotherapy for treatment of neuroendocrine tumors: preliminary experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1631-X

Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1631-X

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1631-X

The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1631-X

Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1631-X

Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1631-X

A software tool for specifying voxel models for dosimetry estimation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1631-X

Validation of a personalized dosimetric evaluation tool (Oedipe) for targeted radiotherapy based on the Monte Carlo MCNPX code.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1631-X

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1631-X

Two-sided confidence intervals for the single proportion: comparison of seven methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1631-X

Probable Inference, the Law of Succession, and Statistical Inference

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1631-X

Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1631-X

Neuroendocrine tumors of the diffuse neuroendocrine system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1631-X

90Y-edotreotide for metastatic carcinoid refractory to octreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1631-X

Defining pharmacokinetics for individual patient dosimetry in routine radiopeptide and radioimmunotherapy of cancer: Australian experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1631-X

Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1631-X

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1631-X

Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1631-X

Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1631-X

Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1631-X

Radiation sensitizers: a selective review of molecules targeting DNA and non-DNA targets

21 January 2018

1 reference

12 December 2020

OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine

1 reference

12 December 2020

Re-evaluation of absorbed fractions for photons and electrons in spheres of various sizes

1 reference

12 December 2020

MIRD pamphlet No. 17: the dosimetry of nonuniform activity distributions--radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee

1 reference

12 December 2020

Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.

1 reference

12 December 2020

Tolerance of normal tissue to therapeutic irradiation

1 reference

12 December 2020

Carcinoid metastases to the liver: role of triple-phase helical CT

1 reference

12 December 2020

A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer

1 reference

12 December 2020

Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use

1 reference

12 December 2020

MIRDOSE: personal computer software for internal dose assessment in nuclear medicine

1 reference

12 December 2020

Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome

1 reference

12 December 2020

10.1007/S00259-010-1631-X

Identifiers

DOI

1 reference

26 July 2017

1 reference